Summary Our previous studies showed that carboxymethyl benzylamide dextran (CMDB7) blocks basic fibroblast growth factor (FGF-2)-dependent cell proliferation of a human breast epithelial line (HBL1 00), suggesting its potential role as a potent antiangiogenic substance. The derived cell line (HH9), which was transformed with the hst/FGF4 gene, has been shown to be highly proliferative in vitro and to induce angiogenic tumours in nude mice. We show here that CMDB7 inhibits the mitogenic activities of the conditioned media from HBL 100 and HH9 cells in a dose-dependent manner. When HH9 cells were injected s.c. into nude mice, CMDB7 treatment (300 mg kg-' week-') suppressed the tumour take and the tumour growth by about 5Oi/o and 80% respectivety. Immunohistochemical analysis showed a highly significant decrease, by more than threefold, in the endothelial density of viable tumour regions, together with a significant increase in the necrosis area. This antiangiogenic activity of CMDB7 was further demonstrated by direct inhibition of calf pulmonary artery (CPAE) and human umbilical vein (HUVEC) endothelial cell proliferation and migration in vitro. In addition, we showed that CMDB7 inhibits specifically the mitogenic effects of the growth factors that bind to hepann such as FGF-2, FGF-4, platelet-derived growth factor (PDGF-BB) and transforming growth factor (TGF-p1), but not those of epidermal growth factor (EGF) and insulin-like growth factor (IGF-1). These results demonstrate that CMDB7 inhibits FGF-2/FGF-4-dependent tumour growth and angiogenesis, most likety by disrupting the autocrine and paracrine effects of growth factors released from the tumour cells.
The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7) mesenchvmal. neuronal and epithelial origin (Basilico and Moscatelli. 1992 : Tanaka et al. 1992 : Mivamoto et al. 1993 . FGFs require heparin as a co-factor for their interaction with the receptors. Although some FGFs do not possess a signal sequence. all of them appear to be secreted and accumulated in the extracellular matrix (Klagsbrun. 1989) . In the human mammary gland. localized in the area of myoepithelial and epithelial cells (Gomm et al. 1991 ) . Clinical studies indicate that these growth factors may be involved in breast cancer development. For example. FGF-1. FGF-2. FGF-receptor I (FGF-RI). FGF-R2 and FGF-R3 gene expression has been detected in breast cancer (Penault-Lorca et al. 1995). and FGF3 and FGF4 genes are up-regulated in 20%c of breast cancer (Theillet et al. 1989 ). In some breast cancer patients FGF-2 is abnormallv elevated in the serum or urine (Takei et al. 1993 : Nguyen et al. 1994 .
A number of studies have shown that FGFs are involved in tumorigenesis and metastasis in vivo (Dickson et al. 1984 : Murakami et al. 1990 : Wellstein et al. 1991 . For example. Received 27 June 1997 Revised 12 November 1997 Accepted 16 December 1997 Correspondence ta: R Baghen-Yarmand cells transfected by FGF4 become tumorigenic and metastatic when xenografted in nude mice. even in the absence of oestrogens (Mcleskev et al. 1993) . FGF-2 exerts angiogenic actixity in viVo (Czubayko et al. 1994 ) and induces proliferation. protease production and migration of endothelial cells in vitro (Sato and Rifkin. 1988 : Tsuboi et al. 1990 : Gualandris et al. 1994 . FGF-2-overexpressing endothelial cells acquire an angiogenic phenotype and recruit quiescent endothelium originating in angioproliferatixve lesions in vivo (Gualandris et al. 1996) .
In previous studies. we have shown that the FGF-2 autocrine path,vAay can be involved in tumour progression. The HBLIOO cells. not tumorigenic in nude mice. produce and secrete FGF-2. wx-hich stimulates their growth in an autocrine manner (Souttou et al. 1994) . The cell lines obtained by transfection of human breast epithelial HBL100 cells w-ith the activated FGF4 oncogene develop colonies in soft agar and produce highly vascularized tumours as a result of the production and secretion of both FGF-2 and FGF4. which can act as autocrine and paracrine factors. But the presence of FGF-1. insulin-like growth factors (IGF-1. IGF-2). transforming growth factors (TGF-cs. TGFS-1) and plateletderived growth factor (PDGF-BB) is not detected in conditioned medium and in cell extracts of HH9 cells (Souttou et al. 1996) . This cell line may provide an appropriate experimental model for studying antitumoral and anti-anciogenesis molecules that act on the autocrine and paracrine regulations of tumour development.
In prexvious papers. w e hax-e show-n that some dextran derivatix es display ed an in -itro growth inhibitorx activitv on breast pretumour and tumour cells dependinc on their composition ()Mor&re et al. 1992: Bagheri-Yarmand et al. 1994 ). For some of them. e.g. carbox-meth\ l benzylamide dextran (CMIDB). a positiVe correlation w-as found betw-een the inhibition of cell proliferation and the oxverall content of benzvlamide. Growxth inhibition w-as associated w-ith a decrease in the proportion of S-phase cells and an accumulation of cells in G phase ) Bagherii-Yarmand et al. 1994) . Recently. >-e show-ed that one member of these dextran derivatixves. CMDB7. could exert its antiproliferative action on HBL100 cells by interfering w-ith the FGF-2 autocrine growth of these cells (BaTheri-Yarmand et al. 1997) . Experimental data that emphasize the orowxth inhibitors potential of this cytostatic non-toxic compound led us to examine the activity of CNIDB7 on the breast cancer experimental model of HH9 tumour in nude mice. In this paper. using this experimental model. >-e investigated the effect of CMDB7 on: (a) the in vitro growth of HH9 cells: (b) the mito2enic actixities of conditioned medium from HBL100 and HH9 cells on fibroblasts and endothelial cells: (c) the tumour take and tumour arowth of HH9 cells in nude mice and the neoxascularization of these tumours: ( d) the in vitro migration and proliferation of endothelial cells and )e) the mitogenic actixities of purified angiogenic growth factors on fibroblasts.
MATERIALS AND METHODS
Dextran derivative preparation W'ater-soluble dextran derivatixve (CMDB7) >-as prepared from dextran T40 as prexiously described (Chaubet et al. 1995 (Lebeau et al. 1991) . The HH9 cell line used in this studx is a clone of HBL 100 cells transformed wxith the FGF-4 oncogene (Souttou et al. 1996) 
Preparation of conditioned medium
Epithelial cells in 150-mm-diameter Petri dishes Polxlabo) w-ere arow-n to 80&e confluence in DMEM supplemented w ith 10c FCS. w-ashed tu-ice wxith DMEM and incubated in 1O ml per dish of DMIEM containin2 0.1%c bovine serum albumin (BSA) (Sigma Chemical Co.. France) for 24h at >7-C. The medium %vas then han-ested. cleared bv centrifugation and stored at -80-C before use. follow-ing 18 h of culture >-as absorbed to a paper filter by a Skatron harvester (Skatron. Lier. Nor-wav) and the radioactivity w-as determined in a liquid scintillation counter. Quadruplicate expenments w-ere repeated at least three times.
Migration assay of endothelial cells
A w-ound >-as created w-ith a scraper in confluent endothelial monolaver in 35-mm tissue culture dishes (Falcon labwarei so as British Joumal of Cancer (1998) 78(1). [111] [112] [113] [114] [115] [116] [117] [118] to destroy half of the monolayer. Culture medium and detached cells were removed. the monolaver washed with culture medium and fresh complete medium added with or without tested aaents. Transparent graph paper was then stuck to the bottom of the tissue culture dishes so that the shifting distance of the edge of migration could be directly measured. The results of the migration distance were expressed as a percentage of the migration rate of the control cells. The experiments were repeated at least three times.
Xenografts in nude mice
Swiss nulnu male athvrmic mice. 3 weeks old. were obtained from Charles River. France. Animals were kept in a temperaturecontrolled room on a 12:12 light-dark schedule with food and water ad libitum. HH9 cells were cultivated in DMEM supplemented with 10% FCS in T150 plates and harvested at 80%7 confluence. Cells (10-) were inoculated s.c. into the right axillary region of the flank of nude mice. One week after the tumour cell inoculation. CMDB7 was injected s.c. close to tumours at a dose of 150 m, kg-' in 0.1 ml of phosphate-buffered saline (PBS). twice a week, for 9 weeks. The control group receised s.c. a 0.1 ml injection of PBS. Tumours were measured along two major axes with calipers. Tumour X olume wAas caculated as follows: V = 0.5 x R, R.
where R is the shortest diameter and R, is the longest diameter. Animals (24 mice) were arbitrarily placed in control (n = 12) and CMDB7 (n = 12) groups.
Tissue storage and immunohistochemical analysis Tumour specimens were fixed with a solution of formalin (4%7c) immediately after surgical resection. The fixed samples were processed to paraffin in the usual way. and 5-gm sections were examined in haematoxylin and eosin preparations. Immunohistochemical staining using a Universal Kit of LSAB2 (K675-DAB: Dako. France) was also performed using monoclonal mouse antibodies against Ki-67 (MIB-l: Immunotech). The number of positive cells for Ki-67 monoclonal antibody was estimated in six high-power fields containing 60-80 cells per field (x 400). Endothelial cells were specifically stained with Griffonia (Banderaea) simplicifolia lectin (GSL-l). The GSL-l lectin binds specifically to a-galactosyl residues and marks the vascular endothelium in mice (Alroy et al. 1987 
RESULTS
Inhibition of the HH9 cell growth by CMDB7 Increasing concentrations of CMDB7 ranging from 1 j-ix to 50 JIM added to HH9 cells resulted in a dose-dependent inhibition of cell number (Figure 1 ). We observed a cytostatic effect of CMDB7
with an IC; of about 25 jix after 8 days of treatment (Figure 1 ).
When CMDB7 was removed from the culture medium after a 4-day treatment cell growth resumed at a rate similar to that observed in untreated cells (data not shown Figure 2B ).
Effect of CMDB7 on HH9 cells xenografted in nude mice
To study the CMDB7 effect on the tumour appearance. one week after s.c. inoculation of 10-exponentiallx grow ing HH9 cells in the right flank of mice. we injected at the same site. tsice per week.
4 mg of CMDB7 per mouse (150 mg kg-'). Palpable tumours appeared in 60%7. 70%c and 90%/ of control mice 3. 4 and 8 weeks after cell injections respectivelv. In mice treated w-ith CMDB7.
palpable tumours appeared in 15%. 40%7 and 50%7 of mice 5. 6 and 10 weeks after cell injection respectivelv ( Figure 3A ). CMDB7 decreased the tumour size by 80%7 after 9 weeks of treatment in the case of treated mice that developed a tumour (P < 0.00001) ( Figure 3B ). Bx measuring proliferating tumour cells w-ith antibodx against nuclear Ki-67 antigen. we showed that all the proliferating activities w ere similar. both in untreated and treated tumours ( Inhibitory effect of CMDB7 on fibroblast stimulation by FGF-2, FGF-4, PDGF-BB and TGF-1 but not EGF and IGF-1
We studied the mitogenic potency of FGF-2. FGF4. PDGF-BB. TGF-4. EGF and IGF-1 in the presence or absence of CMDB7 on Balb/c3T3 fibroblasts. Figure 6 shows that the addition of 2 ng ml-' FGF-2 or FGF4 enhanced the cell growth about nineand sixfold respectively. Under these experimental conditions. Balb/c3T3 DNA synthesis compared with the control (Figure 6 ). Under the same conditions. EGF and IGF-1 enhanced the thymidine uptake by about three-and twofold respectively. So CMDB7
did not effect EGF and IGF-1 growth stimulation ( Figure 6 ).
DISCUSSION
Previous studies have shown that CMDB7 inhibits HBL100 cell growth by interfering with the FGF-2 autocrine loop in these cells (Bagheri-Yarmfand et al. 1997) . (Folkman. 1990 : Kim et al. 1993 (Hon et al. 1991) . suggesting that novel therapeutic approaches to in the level of cancer therapy might involve the use of antiangiogenic drugs.
Inhibition of tumour growth and angiogenesis by dextran derivative 117 In order to explain this CMDB7 antiangiogenic effect, we have tested the CMDB7 effect on endothelial cell proliferation, a key step in the angiogenesis process (Folkman and Klagsbrun, 1987) . CPAE and HUVEC cell proliferation was inhibited by CMDB7. It is unknown whether this inhibition was due to FGF-2-independent mechanisms or the inhibition of an autocrine FGF-2 production by endothelial cells (Schweigerer et al, 1987) . Moreover, this inhibition of endothelial cell proliferation could be due to interference with the binding of angiogenic factors such as FGF-2 or FGF-4 to endothelial cells (Vaisman et al. 1990 ). In accord with this hypothesis. we have shown that CMDB7 binds to FGF-2 and prevents the binding of radiolabelled FGF-2 to its high-and low-affinity receptors on HBL100 cells (Bagheri-Yarnand et al, 1997) . Migration of endothelial cells. which is also a key step in the angiogenesis process. mediated by FGF-2 (Sato and Rifkin. 1988) . appears less sensitive to CMDB7 than does endothelial cell proliferation. Thus, CMDB7 can block neovascularization by directly inhibiting the angiogenic activity of endothelial cells.
Furthermore, the reduction in endothelium density caused by CMDB7 could result from its anti-growth factor activity, blocking paracrine stimulations of FGF-2 and FGF-4 on both fibroblasts and endothelial cells. Growth factors secreted by HBL100 and HH9 cells stimulated the incorporation of [3H]thymidine by quiescent cultures of Balb/c3T3 fibroblasts. As FGF-1. IGF-1. IGF-2. TGF-ct, TGF-.j1 and PDGF-BB are not detected in the conditioned media of HH9 cells. stimulation of the fibroblasts' DNA synthesis by HH9-conditioned medium is essentially due to FGF-2 and FGF-4. The CMDB7 treatment inhibited dose dependently CMinduced mitogenicity in Balb/c3T3 fibroblasts. However. CMDB7 at 5 gM completely blocks the mitogenic effect of factors secreted by HBL100 cells but inhibits partially (63%). at 50 giM, the stimulation induced by CM from HH9 cells. A possible explanation is an insufficient dose of CMDB7 for neutralizing the higher quantity of growth factors secreted in CM from HH9 cells compared with HBL100 cells (Souttou et al, 1996) . The mitogenic effects of purified FGF-2, FGF-4. PDGF-BB and TGF-i1 on Balb/c3T3 fibroblast DNA synthesis is inhibited by CMDB7. In contrast, CMDB7 did not affect DNA stimulation by EGF and IGF-1.
CM from HBLIOO and HH9 cells stimulated the growth of endothelial cells, 15-and 22-fold above the control respectively vs 2.4-and 3.4-fold stimulation on fibroblasts, suggesting that endothelial cells are more sensitive to FGF-2 and FGF-4 factors than fibroblasts. As CMDB7 partially inhibits the paracrine stimulation of conditioned media from HBL100 and HH9 cells on endothelial cells, it is likely that there is not a sufficient amount of CMDB7 to complex completely these angiogenic factors.
It was proposed that tumours might release factors able to stimulate expression, production and release of FGF-2 in and from capillary endothelial cells and so stimulate angiogenesis. Once the tumours are invaded by the capillaries, local release of FGF-2 could further enhance the growth of FGF-sensitive tumours (Schweigerer et al. 1987) . We believe that the in vivo effect of CMDB7 is most probably due to its interaction with the FGF-2 and FGF-4 released from tumours. Mammary stromal fibroblasts may also produce factors that exert influence on the growth and malignant progression of breast tumours via paracrine effects on tumour-associated endothelium (Hatky et al, 1994 ).
In conclusion, the present report shows that CMDB7 is an effective inhibitor of FGF-2 and FGF-4 mitogenic activity for fibroblasts and endothelial cells in vitro and a potent inhibitor for angiogenesis-dependent tumour growth in vivo. Thus, this compound should be an interesting candidate for developing new anti-cancer drugs, not only because of its potent inhibitory effect on tumour induced angiogenesis, but also because of its extremely low toxicity in vitro as well as in vivo.
